Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
0.8000
-0.0510 (-5.99%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
Next >
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
April 21, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
April 21, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
April 04, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
March 28, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
March 10, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
March 09, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
March 06, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
February 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million
February 23, 2023
From
Jeffs' Brands Ltd
Via
GlobeNewswire
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
February 23, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023
Clearmind Medicine submitted patent applications to protect the novel compounds
From
SciSparc Ltd
Via
GlobeNewswire
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
February 22, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
February 17, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc Announces Corporate Restructuring plan
January 25, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
January 23, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
January 18, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
January 17, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
January 09, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
January 05, 2023
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
December 14, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
December 07, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
November 29, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
November 15, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
November 08, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
November 07, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Wellution™ Signs an Agreement with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms
November 01, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
October 28, 2022
From
SciSparc Ltd
Via
GlobeNewswire
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
October 12, 2022
From
SciSparc Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.